HER2 testing in gastric cancer: An update

被引：9

作者：

Lucas Faria Abrahao-Machado ^{[1
]}

Cristovam Scapulatempo-Neto ^{[1
]}

机构：

[1] Department of Pathology, Barretos Cancer Hospital

来源：

World Journal of Gastroenterology | 2016年 / 19期

关键词：

Human epidermal growth factor receptor 2 testing; Gastric cancer; Immunohistochemistry; Scoring system; Trastuzumab;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100214 ;

摘要：

Human epidermal growth factor receptor 2(HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.

引用

页码：4619 / 4625

页数：7

共 15 条

[1] Advanced gastric cancer:Current treatment landscape and future perspectives [J].

Antonia Digklia ;

Anna Dorothea Wagner .

World Journal of Gastroenterology, 2016, (08) :2403-2414

[2]

Recent advances in the HER2 targeted therapy of gastric cancer[J]. Tasuku Matsuoka,Masakazu Yashiro.World Journal of Clinical Cases. 2015(01)

[3]

HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays[J]. Lucas Faria Abraho-Machado,Alexandre Andrade dos Anjos Jácome,Durval Renato Wohnrath,José Sebastio dos Santos,Estela Cristina Carneseca,José Humberto Tavares Guerreiro Fregnani,Cristovam Scapulatempo-Neto.World Journal of Gastroenterology. 2013(38)

[4]

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer[J]. Chao He,Xue-Yi Bian,Xing-Zhi Ni,Dan-Ping Shen,Yan-Ying Shen,Hua Liu,Zhi-Yong Shen,Qiang Liu.World Journal of Gastroenterology. 2013(14)

[5]

Twenty five years since the first prospective study by Forman et al. (1991) on Helicobacter pylori and stomach cancer risk[J] . Freddy Sitas.Cancer Epidemiology . 2016

[6]

HER 2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?[J] . Daniel D. Wong,W. Bastiaan de Boer,Michael A. Platten,Vickie Y. Jo,Edmund S. Cibas,M. Priyanthi Kumarasinghe.Diagn. Cytopathol. . 2015 (1)

[7] Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas [J].

Cho, Eun Yoon ;

Srivastava, Amitabh ;

Park, Kyeongmee ;

Kim, Jiyun ;

Lee, Min Hyeong ;

Do, Ingu ;

Lee, Jeeyun ;

Kim, Kyoung-Mee ;

Sohn, Tae Sung ;

Kang, Won Ki ;

Kim, Sung .

PATHOLOGY, 2012, 44 (03) :216-220

[8] Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer [J].

Barok, Mark ;

Tanner, Minna ;

Koninki, Katri ;

Isola, Jorma .

CANCER LETTERS, 2011, 306 (02) :171-179

[9] HER2 Testing in Gastric Cancer [J].

Albarello, Luca ;

Pecciarini, Lorenza ;

Doglioni, Claudio .

ADVANCES IN ANATOMIC PATHOLOGY, 2011, 18 (01) :53-59

[10] HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing [J].

Rueschoff, Josef ;

Dietel, Manfred ;

Baretton, Gustavo ;

Arbogast, Susanne ;

Walch, Axel ;

Monges, Genevieve ;

Chenard, Marie-Pierre ;

Penault-Llorca, Frederique ;

Nagelmeier, Iris ;

Schlake, Werner ;

Hoefler, H. ;

Kreipe, H. H. .

VIRCHOWS ARCHIV, 2010, 457 (03) :299-307

← 1 2 →